عنوان مقاله:

نویسندگان:

مهدی موسس فر، پانیذ سلامی، کیمیا نوائی، سهیلا دلیلی، رضا عربی میانرودی

Background: Chimeric Antigen Receptor (CAR) T cell therapy has emerged as a transformative approach in cancer treatment, showing significant efficacy in hematologic cancers. However, its application in solid tumors is limited due to challenges such as the tumor microenvironment and antigen heterogeneity. This review aims to highlight the efficacy, safety, and challenges of CAR T cell therapy in both hematologic and solid tumors. Methodology: A comprehensive search of peer-reviewed articles published between 2016 and 2024 was conducted, focusing on clinical outcomes, toxicity profiles, and advancements in CAR T cell engineering. Inclusion criteria encompassed peer-reviewed-English-language studies reporting on these aspects. Editorials, case reports, preclinical studies, presentations, non-English publications, studies outside the specified timeframe, and those lacking relevant CAR T cell data were excluded. Results: The review found that CAR T cell therapy demonstrates high response rates and durable remissions in hematologic cancers such as B-cell leukemia and lymphoma. However, its efficacy in solid tumors remains limited due to the immunosuppressive tumor microenvironment, antigen heterogeneity, and off-target effects. Additionally, significant toxicities, including cytokine release syndrome and neurotoxicity, were commonly reported across studies. Conclusion: While CAR T cell therapy has revolutionized the treatment of certain hematologic cancers, there is a need for improved strategies to enhance its efficacy in solid tumors and to mitigate associated toxicities. Future research should focus on developing multi-targeting CARs to overcome tumor microenvironment barriers, and integrate CAR T cells with other immunotherapies.

CAR T cell therapy, Cancer, Solid tumors, Hematologic cancers, Tumor microenvironment, Immunotherapy

برای لینک‌دهی به این مقاله از آدرس زیر استفاده نمایید:

برای ارجاع در منابع از عبارت زیر استفاده کنید:
موسس فر، مهدی، سلامی، پانیذ، نوائی، کیمیا، دلیلی، سهیلا، عربی میانرودی، رضا، 1404، CAR T Cells در ایمونوتراپی سرطان: شمشیر دولبه پیشرفت‌ ها و چالش‌ ها، کنگره بین المللی زیست پزشکی سرطان و سلولهای بنیادی، http://conf.sums.ac.ir/fa/archive_index.php?c=HN-icsbc1&aid=1514177